Q2 FY2026 · ended Jun 30, 2026 · Revenue $1.10M, +3.1% YoY · Filed Aug 14, 2026
NRX Pharmaceuticals, Inc. (NRXP) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $1.1 million and a net loss of $16.5 million. Free cash flow was -$9.8 million. As of Jun 30, 2026 it held $26.7 million in cash and investments and $834,000 in total debt.
Revenue
$1.10M
+3.1% vs prior quarter
Net income
$-16.52M
-1055.2% vs prior quarter
Operating cash flow
$-8.88M
-106.6% vs prior quarter
Free cash flow
$-9.77M
-180.8% vs prior quarter
EPS
$-0.07
Dividend per share
None
Shares outstanding
43.30M
+19.5% vs prior quarter
Net cash
$25.85M
Q2 FY2026
Operating margin
-590.8%
Q2 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NRXP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmington, DE
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1719406
- Former names
- Big Rock Partners Acquisition Corp. (until May 24, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q2 FY2024 Jun 30, 2025 |
Q1 FY2024 Mar 31, 2025 |
Q4 FY2024 Dec 31, 2024 |
|---|---|---|---|---|---|
| Revenue | $1.1M | $1.1M | $0 | $0 | $0 |
| Operating income | -$6.5M | -$4.7M | -$3.7M | — | -$2.4M |
| Net income | -$16.5M | -$1.4M | -$17.6M | -$5.5M | -$9.1M |
| Operating cash flow | -$8.9M | -$4.3M | -$4.0M | -$3.5M | -$2.1M |
| Free cash flow | -$9.8M | — | — | -$3.5M | -$2.1M |
| Total assets | $34.2M | $11.9M | $4.8M | $7.6M | $3.7M |
| Total liabilities | $34.3M | $25.7M | $40.5M | $32.8M | $26.9M |
| Stockholders' equity | -$170,000 | -$13.8M | -$35.6M | -$25.2M | -$23.2M |
| Cash and investments | $26.7M | $6.7M | $2.9M | $5.5M | $1.4M |
| Total debt | $834,000 | $934,000 | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 2, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 16, 2026 | Oct 16, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 5, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Other events
|
Sep 16, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 14, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 17, 2026 | Aug 17, 2026 |
All 479 NRX Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.